Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 6/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | KDM5C | P41229 | 3/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | KDM3A | Q9Y4C1 | 2/20 | 0.33 |
| ▸ | KDM6B | O15054 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18367646 | 0.91 | HTR6 (0.38) | DRD4SIGMAR1DRD2KCNH2DRD3 | |
| SCHEMBL18367651 | 0.91 | HTR6 (0.38) | DRD4SIGMAR1DRD2KCNH2DRD3 | |
| SCHEMBL19726576 | 0.91 | HTR6 (0.38) | DRD4SIGMAR1DRD2KCNH2DRD3 | |
| SCHEMBL18367644 | 0.84 | ALDH1A1 (0.33) | ALDH1A1HRH3KDM5CKDM2AKDM4C | |
| SCHEMBL18367636 | 0.84 | DRD4 (0.38) | DRD4SIGMAR1DRD2KCNH2DRD3 | |
| SCHEMBL18367661 | 0.84 | RET (0.36) | DRD4SIGMAR1DRD2KCNH2DRD3 | |
| SCHEMBL18367632 | 0.83 | DRD4 (0.37) | DRD4SIGMAR1DRD2KCNH2DRD3 | |
| SCHEMBL18367630 | 0.82 | IRAK4 (0.38) | DRD4SIGMAR1DRD2KCNH2DRD3 | |
| SCHEMBL18367582 | 0.81 | DRD2 (0.33) | DRD4SIGMAR1DRD2KCNH2DRD3 | |
| SCHEMBL18367634 | 0.81 | DRD2 (0.33) | DRD4SIGMAR1DRD2KCNH2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316017-B2 | COT modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9815818-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815818-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362201-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | DRD4 4722/4885SIGMAR1 978/4885DRD2 4763/4885 |
| US-10316017-B2 | COT modulators and methods of use thereof | BRDT, THRB, HCCS | DRD4 4722/4885SIGMAR1 978/4885DRD2 4763/4885 |
| US-20170008873-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | DRD4 4722/4885SIGMAR1 978/4885DRD2 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.